26 completed, 9 terminated, 8 unknown, 6 recruiting. 55 Phase 2, 6 Phase 3, 4 Phase 1.
Follow Mitomycin c: new trials by email Literature Review of Mitomycin c trials Research Report on Mitomycin c
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Risk-Enabled Therapy After Initiating EV/Pembro for Bladder Cancer Enfortumab vedotin, Pembrolizumab, Cisplatin - Bladder Cancer, Urothelial Carcinoma | Phase 2 | Recruiting | Fox Chase Cancer Center | 70 | 2026-10-16 | 2026-11-02 |
| Combined Systemic and Intraperitoneal Chemotherapy for Synchronous Gastric and/or Gastroesophageal Peritoneal Carcinomatosis Cisplatin, Mitomycin C - Synchronous Gastric Peritoneal Carcinomatosis, Gastroesophageal Peritoneal Carcinomatosis | Phase 2 | Recruiting | Mohammad Haroon Asif Choudry | 22 | 2026-09-29 | 2026-10-22 |
| Metronomic Gemcitabine, Mitomycin C, and Thalidomide for Advanced Solid Tumors Gemcitabine, Mitomycin C, Thalidomide - Solid Tumor Cancer | Phase 2 | Recruiting | Sarcoma Oncology Research Center, LLC | 60 | 2026-06-01 | 2026-06-26 |
| Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial Biospecimen Collection, Cisplatin, Computed Tomography - Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 160 | 2025-06-03 | 2026-11-09 |
| In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial BCG Solution, Cystoscopy, Docetaxel - Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 40 | 2025-04-21 | 2026-10-08 |
| REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation Radiation (reduced elective nodal dose (30.6 Gy), Capecitabine, Mitomycin c - Anal Cancer | Phase 2 / Phase 3 | Active not recruiting | University of Cincinnati | 33 | 2023-08-14 | 2025-12-18 |
| Phase II Trial of Lung Chemoemobolization Computed Tomography, Ethiodized Oil, Mitomycin - Lung Non-Small Cell Carcinoma, Mediastinal Neoplasm | Phase 2 | Recruiting | City of Hope Medical Center | 30 | 2023-05-12 | 2026-03-05 |
| Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer Anoscopy, Biospecimen Collection, Capecitabine - AIDS-Related Anal Carcinoma, Anal Margin Squamous Cell Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 40 | 2022-08-09 | 2026-10-05 |
| Intralesional Injection of Mitomycin C Following Visual Internal Urethrotomy for Recurrent Urethral Stricture Mitomycin c - Urethral Stricture | Phase 2 / Phase 3 | Completed | Ain Shams University | 50 | 2022-01-01 | 2024-01-30 |
| A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial Biopsy of Bladder, Biospecimen Collection, Cisplatin - Bladder Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8 | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 11 | 2021-03-17 | 2026-05-22 |
| Efficacy of Topical Mitomycin C for Complex Benign Esophageal Anastomotic Strictures Mitomycin C, Control - Esophageal Stenosis, Anastomotic Stenosis | Phase 2 | Withdrawn | Fox Chase Cancer Center | 2020-04-03 | 2022-04-11 | |
| Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study Biopsy, Biospecimen Collection, Capecitabine - Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma | Phase 2 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 252 | 2020-01-02 | 2026-10-19 |
| Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma Mitomycin c - Urothelial Carcinoma | Phase 2 | Completed | University of Florida | 29 | 2018-12-05 | 2024-11-05 |
| Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer Avelumab, Cisplatin, Fluorouracil - Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Stage II Bladder Cancer AJCC v8 | Phase 2 | Completed | Mayo Clinic | 2 | 2018-09-19 | 2023-01-06 |
| Comparing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) Using Mitomycin-C Versus Melphalan for Colorectal Peritoneal Carcinomatosis Mitomycin c, Melphalan - Cancer, Appendiceal, ColoRectal Cancer | Phase 2 | Unknown | University of Kansas Medical Center | 100 | 2017-07-14 | 2023-06-09 |
| Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology Surgery, Cisplatin, Mitomycin C - Gastric Adenocarcinoma, Esophagogastric Junction | Phase 2 | Completed | National Cancer Institute (NCI) | 27 | 2017-06-05 | 2025-02-19 |
| Heated Mitomycin and Cisplatin During Surgery in Treating Patients With Stomach or Gastroesophageal Cancer Cisplatin, Hyperthermic Intraperitoneal Chemotherapy, Mitomycin - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 24 | 2016-09-01 | 2024-09-19 |
| Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN) Methotrexate, Vinblastine, Doxorubicin - Urothelial Carcinoma of the Bladder | Phase 2 | Completed | Fox Chase Cancer Center | 78 | 2016-02-24 | 2026-05-22 |
| Study of IMRT Radiotherapy Concurrent Chemothrerapy for Anal Cancer Chemo-radiotherapy with IMRT technique, Capecitabine, Mitomycin C - Anal Cancer | Phase 2 | Unknown | Chinese Academy of Medical Sciences | 27 | 2015-12-02 | 2018-01-30 |
| Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients 120 mg MMC in 90ml gel, 140 mg MMC in 90ml gel, 160 mg MMC in 90ml gel - Bladder Cancer, Neoplasms | Phase 2 | Completed | UroGen Pharma Ltd. | 14 | 2014-12-01 | 2017-06-16 |
Showing 20 of 55. Sign in to see all of them.
Urinary Bladder Neoplasms (10) · Anus Neoplasms (6) · Colorectal Neoplasms (5) · Neoplasm Metastasis (5) · Appendiceal Neoplasms (4) · Colonic Neoplasms (4) · Glaucoma (4) · Non-Muscle Invasive Bladder Neoplasms (4) · Rectal Neoplasms (4) · Sarcoma (4) · Carcinoma, Transitional Cell (3) · Pancreatic Neoplasms (3) · Peritoneal Neoplasms (3) · Stomach Neoplasms (3) · Anal Canal Carcinoma (2)
National Cancer Institute (NCI) (4) · Fox Chase Cancer Center (3) · Mayo Clinic (3) · European Organisation for Research and Treatment of Cancer - EORTC (2) · Gynecologic Oncology Group (2) · M.D. Anderson Cancer Center (2) · UNICANCER (2) · Ain Shams University (1) · Albert Einstein College of Medicine (1) · Athens Vision Eye Institute (1) · British Thoracic Society (1) · CG Oncology, Inc. (1) · Centro Nacional de Investigaciones Oncologicas CARLOS III (1) · Chinese Academy of Medical Sciences (1) · City of Hope Medical Center (1)
United States (35) · France (4) · Belgium (3) · Italy (3) · United Kingdom (3) · Canada (2) · Egypt (2) · Israel (2) · Netherlands (2) · China (1) · Denmark (1) · Germany (1) · India (1) · Norway (1) · Portugal (1)
Dominique Elias, MD (2) · Aldo V. Bono, MD (1) · Alex W Yeung, MBBS (1) · Brian C Baumann (1) · Brian D Badgwell (1) · Brian D. Badgwell, MD (1) · Carsten Bokemeyer, MD (1) · Daniel A. Laheru, MD (1) · David J. Girling, MD (1) · Edward Levine (1) · Finn O Larsen, M.D., Ph.D (1) · Franz E Boas, MD (1)
PMID 12051882, PMID 16051328, PMID 17470859, PMID 19643599, PMID 20354452, PMID 20570237, PMID 21135251, PMID 21156335, PMID 28643069, PMID 32067679, PMID 32124514, PMID 32556731, PMID 33660142, PMID 34125951, PMID 37611799, PMID 39680823, PMID 41074972
U10CA180820 (2), P30CA006973 (1), P30CA015083 (1), P30CA033572 (1), U10CA032102 (1), U10CA180868 (1), UL1TR002377 (1), UM1CA121947 (1)